Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study.

Haematologica·2024

Same author

International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.

The Lancet. Oncology·2024

Same author

Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.

Cancer medicine·2023

Same author

CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?

Haematologica·2023

Same author

Response to Caravita di Toritto and Rago.

European journal of haematology·2022

Same author

Conditioning with melphalan 200 mg/m<sup>2</sup> and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care.

European journal of haematology·2022

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Allogeneic transplantation in multiple myeloma.

Gösta Gahrton¹

¹Department of Medicine, Karolinska Institutet and Karolinska University Hospital Huddinge, Stockholm, Sweden. gosta.gahrton@ki.se

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer

|April 22, 2011

Summary

Allogeneic stem cell transplants for multiple myeloma offer a potential cure via high-dose treatment and graft-versus-myeloma effects. Reduced intensity conditioning (RIC) improves outcomes, with tandem autologous-RIC-allogeneic transplantation showing superiority.

More Related Videos

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 2, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Area of Science:

Hematology
Oncology
Immunology

Background:

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been used for multiple myeloma since the 1980s.
The goal is curative, leveraging myeloablation and graft-versus-myeloma (GVM) effects.
High transplant-related mortality with myeloablative conditioning has led to the adoption of reduced intensity conditioning (RIC).

Purpose of the Study:

To evaluate the efficacy of different allogeneic stem cell transplantation strategies in multiple myeloma.
To compare tandem autologous-RIC-allogeneic transplantation with autologous stem cell transplantation alone.
To explore novel therapeutic approaches for improving outcomes.

Main Methods:

Review of prospective clinical trials comparing tandem autologous-RIC-allogeneic transplantation with autologous stem cell transplantation (ASCT).
Analysis of outcomes in multiple myeloma patients undergoing allo-HSCT.
Investigation of the impact of reduced intensity conditioning (RIC) versus myeloablative conditioning.

Main Results:

Tandem autologous-ASCT followed by RIC-allogeneic transplantation (RIC-allo) demonstrated superior outcomes compared to tandem or single ASCT.
RIC has improved outcomes and reduced transplant-related mortality compared to myeloablative conditioning.
Ongoing research explores integrating new drugs and alternative cell therapies.

Conclusions:

Tandem autologous-RIC-allogeneic transplantation is a promising approach for multiple myeloma.
Reduced intensity conditioning has enhanced the safety and efficacy of allo-HSCT.
Future strategies may involve combination therapies including novel agents and cellular treatments.